JP7267546B2 - アミノ酸組成物及びその使用 - Google Patents

アミノ酸組成物及びその使用 Download PDF

Info

Publication number
JP7267546B2
JP7267546B2 JP2019539737A JP2019539737A JP7267546B2 JP 7267546 B2 JP7267546 B2 JP 7267546B2 JP 2019539737 A JP2019539737 A JP 2019539737A JP 2019539737 A JP2019539737 A JP 2019539737A JP 7267546 B2 JP7267546 B2 JP 7267546B2
Authority
JP
Japan
Prior art keywords
cells
therapeutically effective
composition
liter
grams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019539737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530750A5 (enExample
JP2019530750A (ja
Inventor
ビドヤサガー，サダシバン
グプタ，レシュ
イン，リアンジエ
グロッシェ，アストリッド
オクニエフ，ポール，ガーソン
ガット，ステフェン
デニソン，ダニエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amilyfe LLC
Original Assignee
Entrinsic LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entrinsic LLC filed Critical Entrinsic LLC
Publication of JP2019530750A publication Critical patent/JP2019530750A/ja
Publication of JP2019530750A5 publication Critical patent/JP2019530750A5/ja
Priority to JP2023060554A priority Critical patent/JP7593577B2/ja
Application granted granted Critical
Publication of JP7267546B2 publication Critical patent/JP7267546B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019539737A 2016-10-04 2017-10-04 アミノ酸組成物及びその使用 Active JP7267546B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023060554A JP7593577B2 (ja) 2016-10-04 2023-04-04 アミノ酸組成物及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662403965P 2016-10-04 2016-10-04
US62/403,965 2016-10-04
US201662421443P 2016-11-14 2016-11-14
US62/421,443 2016-11-14
PCT/US2017/055167 WO2018067717A1 (en) 2016-10-04 2017-10-04 Amino acid compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023060554A Division JP7593577B2 (ja) 2016-10-04 2023-04-04 アミノ酸組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2019530750A JP2019530750A (ja) 2019-10-24
JP2019530750A5 JP2019530750A5 (enExample) 2020-11-12
JP7267546B2 true JP7267546B2 (ja) 2023-05-02

Family

ID=61831937

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019539737A Active JP7267546B2 (ja) 2016-10-04 2017-10-04 アミノ酸組成物及びその使用
JP2023060554A Active JP7593577B2 (ja) 2016-10-04 2023-04-04 アミノ酸組成物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023060554A Active JP7593577B2 (ja) 2016-10-04 2023-04-04 アミノ酸組成物及びその使用

Country Status (9)

Country Link
US (1) US11576884B2 (enExample)
EP (1) EP3522882A4 (enExample)
JP (2) JP7267546B2 (enExample)
CN (2) CN115645388B (enExample)
AU (1) AU2017338887B2 (enExample)
BR (1) BR112019006742A2 (enExample)
CA (2) CA3135553C (enExample)
MX (1) MX2019003821A (enExample)
WO (1) WO2018067717A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030970B8 (ru) 2010-09-24 2019-01-31 Юниверсити Оф Флорида Рисёч Фаундейшн, Инк. Композиция для восстановления функции тонкого кишечника, способы ее приготовления и применения
EP4417256A3 (en) 2013-03-11 2024-10-23 University of Florida Research Foundation, Inc. Materials and methods for improving lung function
US20230255916A1 (en) * 2016-10-04 2023-08-17 University Of Florida Research Foundation, Inc. Amino acid compositions and uses thereof
JP2021520351A (ja) * 2018-04-04 2021-08-19 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 皮膚を治療するための組成物
WO2020028129A1 (en) * 2018-07-30 2020-02-06 Almeda Labs Llc Cardioprotective amino acid formulations
RU2709502C1 (ru) * 2019-09-23 2019-12-18 Виктор Александрович Сисев Фармацевтическая композиция для парентерального капельного введения
WO2021142514A1 (en) * 2020-01-13 2021-07-22 Monash University Compositions and methods
JP7470376B2 (ja) * 2020-03-31 2024-04-18 国立大学法人山口大学 顎下腺の萎縮抑制剤及び創傷治癒促進剤
IL299488A (en) * 2020-07-02 2023-02-01 Univ Florida Preparations for promoting hydration and methods of using them
CN114097952A (zh) * 2020-08-28 2022-03-01 河北科星药业有限公司 毛丝鼠专用的营养添加剂、其制备方法及应用
JP2025501331A (ja) * 2022-01-03 2025-01-17 エントリンジック，エルエルシー スキンケアのための製剤及び方法
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein
CN117085142A (zh) * 2023-08-04 2023-11-21 中山大学附属第七医院(深圳) 一种负载小分子药物的间充质干细胞外泌体及其制备方法与应用
CN117159520B (zh) * 2023-08-17 2026-04-07 中国人民解放军海军军医大学第一附属医院 竹红菌甲素在制备抑制胰腺纤维化的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512522A (ja) 2013-03-11 2016-04-28 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 肺機能を改善するためならびに放射線誘発肺合併症の予防および／または処置のための物質および方法
WO2016085735A1 (en) 2014-11-24 2016-06-02 Entrinsic Health Solutions, Llc Amino acid compositions for the treatment of symptoms of disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016758A1 (en) 1991-03-05 1994-08-04 Miris Medical Corporation A medication cassette for an automatic aerosol medication delivery system
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
CA2210499A1 (en) 1995-02-23 1996-08-29 Novartis Nutrition Ag Amino acid compositions and use thereof in a clinical nutrition
AU5806998A (en) 1996-12-31 1998-07-31 Inhale Therapeutic Systems Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
AU776679B2 (en) 1998-11-13 2004-09-16 Children's Hospital Of Los Angeles Methods of facilitating vascular growth
GB0009056D0 (en) 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
CA2557814A1 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
US20070010459A1 (en) 2005-01-14 2007-01-11 Ying Liu Application of asiatic acid and its derivatives to treat pulmonary fibrosis
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US8691213B2 (en) * 2006-08-04 2014-04-08 SHS International Protein free formula
BRPI0814745A2 (pt) 2007-08-03 2014-10-07 Aminotech As Composição de produto.
JP5576097B2 (ja) * 2009-11-17 2014-08-20 大塚製薬株式会社 気道抵抗改善剤
IT1396935B1 (it) 2009-11-26 2012-12-20 Solartium Entpr Ltd Uso di una combinazione per il trattamento delle mucositi indotte da radiazioni o da chemioterapici
IT1397023B1 (it) * 2009-11-27 2012-12-20 Professional Dietetics Srl Composizioni comprendenti amminoacidi, per il trattamento della broncopneumopatia cronica ostruttiva
BR112012016869A2 (pt) 2010-01-08 2015-09-01 President And Fellows Harvard College Método e revestimentos para tratar biofilmes.
EA030970B8 (ru) 2010-09-24 2019-01-31 Юниверсити Оф Флорида Рисёч Фаундейшн, Инк. Композиция для восстановления функции тонкого кишечника, способы ее приготовления и применения
JP2012214451A (ja) * 2011-03-25 2012-11-08 En Otsuka Pharmaceutical Co Ltd 炎症性疾患用アミノ酸組成物
EP2793813A1 (en) * 2011-12-21 2014-10-29 Motolese, Pasquale Cosmetic composition and uses thereof in the treatment of lipodystrophies
EA034014B1 (ru) 2012-02-08 2019-12-19 Юниверсити Оф Флорида Рисёч Фаундейшн, Инк. Способ лечения субъекта с диареей, вызванной ротавирусом
DE102013224993A1 (de) * 2013-12-05 2015-06-11 Henkel Ag & Co. Kgaa Haarbehandlungsmittel mit substituierten Silikon(en)
US10413528B2 (en) * 2014-10-20 2019-09-17 John H. Plumb Methods to inhibit infection during wound healing with topical compositions including amino acids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512522A (ja) 2013-03-11 2016-04-28 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 肺機能を改善するためならびに放射線誘発肺合併症の予防および／または処置のための物質および方法
WO2016085735A1 (en) 2014-11-24 2016-06-02 Entrinsic Health Solutions, Llc Amino acid compositions for the treatment of symptoms of disease

Also Published As

Publication number Publication date
EP3522882A4 (en) 2020-06-24
CA3135553A1 (en) 2018-04-12
CN115645388A (zh) 2023-01-31
JP7593577B2 (ja) 2024-12-03
US11576884B2 (en) 2023-02-14
MX2019003821A (es) 2019-12-18
AU2017338887B2 (en) 2020-09-03
CN110062621B (zh) 2022-11-01
JP2023100617A (ja) 2023-07-19
CN115645388B (zh) 2024-12-10
US20210283081A1 (en) 2021-09-16
CA3135553C (en) 2024-05-21
CN110062621A (zh) 2019-07-26
AU2017338887A1 (en) 2019-05-02
EP3522882A1 (en) 2019-08-14
CA3039514A1 (en) 2018-04-12
BR112019006742A2 (pt) 2019-09-03
WO2018067717A1 (en) 2018-04-12
JP2019530750A (ja) 2019-10-24
CA3039514C (en) 2022-01-25

Similar Documents

Publication Publication Date Title
JP7593577B2 (ja) アミノ酸組成物及びその使用
Cheng et al. Metformin attenuates silica-induced pulmonary fibrosis via AMPK signaling
KR102709096B1 (ko) 종양 성장 억제 물질 및 방법
JP2021520351A (ja) 皮膚を治療するための組成物
CN116390723B (zh) 用于将生物素递送至线粒体的方法和组合物
WO2022184091A1 (zh) 透明质酸在用于制备预防或治疗铁死亡相关疾病的药物中的应用
JP6900324B2 (ja) 抗微生物ペプチド
US20230255916A1 (en) Amino acid compositions and uses thereof
US20210145806A1 (en) Methods of Treating Brain Cancer and Related Diagnostic Methods
BR122024018467A2 (pt) Formulações de aminoácido e usos das mesmas
TWI672147B (zh) 以外源性粒線體爲有效成份之組合物、其用途及修復細胞之方法
TWI800707B (zh) 使用一包含有薑黃素以及聚乙烯吡咯烷酮的組成物來對抗金黃色葡萄球菌的生物膜
Weinzierl Strategies for increasing tissue survival in critically perfused musculocutaneous flaps
KR20260061032A (ko) 인간 전분화능 줄기세포 유래의 유사 중간엽줄기세포를 유효성분으로 포함하는 허혈성 뇌졸중 후유장애 예방 또는 치료용 조성물
WO2016074203A1 (zh) 包含二氧化氯的细胞凋亡诱导剂及其在制备化妆品或抗衰老或抗肿瘤药物中的用途
Shen et al. Cytological basis of hypoxic preconditioned hUC-MSCs enhance the effect of treating ALI
WO2022150362A1 (en) Poly-arginine derivatives for enhancing brain-derived growth factor to mitigate neurological disorders
WO2025111563A1 (en) Milk peptide compositions for pharmaceutical and cosmeceutical use
US20200361995A1 (en) Apratyramide therapeutic agents and methods of treatment
Abzaeva et al. Pharmacological activity of ziacryl, a zinc salt of polyacrylic acid.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230404

R150 Certificate of patent or registration of utility model

Ref document number: 7267546

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250